NASDAQ:WINT Windtree Therapeutics (WINT) Stock Price, News & Analysis → Trump’s “Tax Free” Retirement Strategy (From Gold Safe Exchange) (Ad) Free WINT Stock Alerts $0.35 -0.01 (-3.78%) (As of 04:00 PM ET) Add Compare Share Share Today's Range$0.35▼$0.3750-Day Range$0.31▼$0.5152-Week Range$0.28▼$18.48Volume28,516 shsAverage Volume273,588 shsMarket Capitalization$1.82 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Windtree Therapeutics alerts: Email Address Windtree Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.41% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.96Based on 7 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.34) to ($1.39) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.16 out of 5 stars N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Windtree Therapeutics. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.41% of the float of Windtree Therapeutics has been sold short.Short Interest Ratio / Days to CoverWindtree Therapeutics has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Windtree Therapeutics has recently decreased by 47.77%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldWindtree Therapeutics does not currently pay a dividend.Dividend GrowthWindtree Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for WINT. Previous Next 3.3 News and Social Media Coverage News SentimentWindtree Therapeutics has a news sentiment score of 0.96. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Windtree Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 7 people have searched for WINT on MarketBeat in the last 30 days. This is a decrease of -22% compared to the previous 30 days.MarketBeat Follows1 people have added Windtree Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Windtree Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.54% of the stock of Windtree Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 29.33% of the stock of Windtree Therapeutics is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Windtree Therapeutics are expected to grow in the coming year, from ($4.34) to ($1.39) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Windtree Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Windtree Therapeutics is -0.02, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioWindtree Therapeutics has a P/B Ratio of 0.03. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Gold Safe ExchangeTrump’s “Tax Free” Retirement Strategy Since 1924 — over one hundred years — the US dollar has lost nearly 18x its value. In other words, a dollar back then would buy $17.82 worth of goods in today's money. If you're planning on retiring any time soon…This poses a real problem.Protect your retirement savings from the inevitable devaluation of the dollar… About Windtree Therapeutics Stock (NASDAQ:WINT)Windtree Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company's lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. Windtree Therapeutics, Inc. has a scientific collaboration with Chang Gung University for cardiovascular diseases of SERCA2a; collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sales of a portfolio of potential KL4 surfactant products; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.Read More WINT Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart WINT Stock News HeadlinesMarch 28, 2024 | americanbankingnews.comWindtree Therapeutics (WINT) to Release Quarterly Earnings on FridayMarch 28, 2024 | americanbankingnews.comWindtree Therapeutics (WINT) Scheduled to Post Earnings on FridayMarch 28, 2024 | Crypto 101 Media (Ad)Crypto Market Preps For Trillions Worth of Inflows! Bitcoin is rapidly approaching new ALL-TIME HIGHS… The market is buzzing after recent approval of spot Bitcoin exchange-traded funds (ETF). Top analysts predict these ETFs will attract trillions of dollars worth of inflows over the next few years… And as Bitcoin rallies, we could see other smaller coins rise to heights never seen before.March 28, 2024 | americanbankingnews.comWindtree Therapeutics, Inc. (NASDAQ:WINT) Sees Large Decline in Short InterestMarch 23, 2024 | americanbankingnews.comWindtree Therapeutics (NASDAQ:WINT) Trading 1.4% Higher February 2, 2024 | msn.comWindtree Therapeutics Seeks Strategic Alternatives with Ladenburg ThalmannFebruary 1, 2024 | finance.yahoo.comWindtree Renews Agreement with Chang Gung University for Scientific Collaboration to Further SERCA2a ResearchJanuary 31, 2024 | bizjournals.comWindtree Therapeutics hires investment bank to explore M&A optionsMarch 28, 2024 | DTI (Ad)the most reliable asset on earth is making a comebackGlobal tensions have been pushing the price of gold to all time highs… Just recently, gold peaked at a record $2,000 (and is now closer to $2,200). And there’s something else critical at play right now in the world’s largest asset. Because of these critical factors, a lot of massive investment institutions are now pumping more money into gold. And as we speak, some are even calling for a massive rally in the precious metal.January 31, 2024 | finance.yahoo.comWindtree Therapeutics Announces Engagement of Strategic Advisor to Support Assessment of Strategic AlternativesJanuary 29, 2024 | benzinga.comWindtree Therapeutics – This Biotech Inks License Deal For Lead CandidateJanuary 26, 2024 | finanznachrichten.deWindtree Therapeutics Eliminates $15 Million Contingent Liability To Deerfield Management CompanyJanuary 26, 2024 | finance.yahoo.comWindtree Therapeutics (NASDAQ:WINT) Eliminates $15 Million Contingent Liability To Deerfield Management CompanyJanuary 25, 2024 | benzinga.comWindtree Therapeutics (NASDAQ: WINT) Eliminates $15 Million Contingent Liability To Deerfield Management CompanyJanuary 25, 2024 | finance.yahoo.comWindtree Eliminates $15 Million Contingent Liability to Deerfield Management CompanyJanuary 24, 2024 | money.usnews.comWindtree Therapeutics IncJanuary 18, 2024 | msn.comWindtree and Lee’s sign licence deal for heart failure therapyJanuary 18, 2024 | finance.yahoo.comUp To $138 Million in Milestones, Up To Low Double Digit Royalties: Windtree Announces Agreement To Develop And Commercialize Drug Candidates In Greater ChinaJanuary 17, 2024 | bizjournals.comWindtree Therapeutics signs drug licensing deal valued at up to $138M with Chinese drug companyJanuary 17, 2024 | finance.yahoo.comWindtree Therapeutics Announces License Agreement with Lee’s Pharmaceuticals to Develop and Commercialize Istaroxime, Dual Mechanism SERCA2a Activators and Rostafuroxin for Greater China / Asia Pacific RegionJanuary 4, 2024 | markets.businessinsider.comHold Rating on Windtree Therapeutics Pending Key Istaroxime StudiesJanuary 3, 2024 | msn.comHC Wainwright & Co. Initiates Coverage of Windtree Therapeutics (WINT) with Neutral RecommendationJanuary 2, 2024 | markets.businessinsider.comWindtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a ActivatorJanuary 2, 2024 | finance.yahoo.comWindtree Therapeutics Announces Reduction In Arrythmias In A New Study With Istaroxime And A Pure SERCA2a ActivatorDecember 19, 2023 | finance.yahoo.comIstaroxime Update: Start Of Patient Dosing In Early Cardiogenic Shock SEISMiC Extension Study In Preparation For Phase 3 Readiness, Topline Data Expected Mid-2024December 18, 2023 | finance.yahoo.comWindtree Therapeutics Announces the Start of Patient Dosing In Phase 2 SEISMiC Extension Study of Istaroxime in Early Cardiogenic ShockNovember 16, 2023 | finance.yahoo.comWindtree Therapeutics Announces Issuance of New Pure SERCA2a Activator PatentSee More Headlines Receive WINT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Windtree Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings4/03/2023Today3/28/2024Next Earnings (Estimated)4/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:WINT CUSIPN/A CIK946486 Webwww.windtreetx.com Phone(215) 488-9300Fax215-488-9301Employees20Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($20.27) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-39,210,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-274.89% Return on Assets-66.31% Debt Debt-to-Equity Ratio2.00 Current Ratio2.40 Quick Ratio2.40 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$12.97 per share Price / Book0.03Miscellaneous Outstanding Shares5,148,000Free Float5,120,000Market Cap$1.85 million OptionableNot Optionable Beta0.60 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Craig E. Fraser (Age 59)Chairman, President, CEO & Interim Principal Officer Comp: $553.75kDr. Steven G. Simonson (Age 65)Senior VP & Chief Medical Officer Comp: $446.1kMr. Eric L. Curtis M.B.A. (Age 56)Senior VP & COO Comp: $526.25kMs. Jamie McAndrew (Age 44)VP, Controller & Chief Accounting Officer Mr. George Cox (Age 72)Vice President of Technical Operations Dr. Pratap ParuchuruExecutive Director of Clinical DevelopmentMs. Tracy RarickHead of Operations & Program ManagementMore ExecutivesKey CompetitorsSQZ BiotechnologiesNYSE:SQZTC BiopharmNASDAQ:TCBPScinai ImmunotherapeuticsNASDAQ:SCNIEloxx PharmaceuticalsNASDAQ:ELOXNanoString TechnologiesNASDAQ:NSTGQView All CompetitorsInsiders & InstitutionsVirtu Financial LLCBought 38,877 shares on 2/26/2024Ownership: 0.755%Citadel Advisors LLCBought 38,128 shares on 2/15/2024Ownership: 0.741%Craig FraserBought 2,500 shares on 9/26/2023Total: $2,250.00 ($0.90/share)Craig FraserBought 1,315 shares on 4/25/2023Total: $2,485.35 ($1.89/share)View All Insider TransactionsView All Institutional Transactions WINT Stock Analysis - Frequently Asked Questions Should I buy or sell Windtree Therapeutics stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" WINT shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in WINT, but not buy additional shares or sell existing shares. View WINT analyst ratings or view top-rated stocks. How have WINT shares performed in 2024? Windtree Therapeutics' stock was trading at $0.7190 at the start of the year. Since then, WINT stock has decreased by 49.9% and is now trading at $0.3602. View the best growth stocks for 2024 here. Are investors shorting Windtree Therapeutics? Windtree Therapeutics saw a decrease in short interest in the month of March. As of March 15th, there was short interest totaling 30,500 shares, a decrease of 47.8% from the February 29th total of 58,400 shares. Based on an average trading volume of 271,200 shares, the short-interest ratio is currently 0.1 days. Currently, 0.4% of the company's stock are sold short. View Windtree Therapeutics' Short Interest. When is Windtree Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, April 1st 2024. View our WINT earnings forecast. How were Windtree Therapeutics' earnings last quarter? Windtree Therapeutics, Inc. (NASDAQ:WINT) issued its quarterly earnings data on Monday, April, 3rd. The company reported ($13.01) EPS for the quarter, missing analysts' consensus estimates of ($10.50) by $2.51. When did Windtree Therapeutics' stock split? Shares of Windtree Therapeutics reverse split on the morning of Thursday, February 23rd 2023. The 1-50 reverse split was announced on Thursday, February 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. Who are Windtree Therapeutics' major shareholders? Windtree Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Virtu Financial LLC (0.75%) and Citadel Advisors LLC (0.74%). Insiders that own company stock include Craig Fraser, Eric Curtis, James Huang, John P Hamill and Steven Simonson. View institutional ownership trends. How do I buy shares of Windtree Therapeutics? Shares of WINT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:WINT) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm Press“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryMost important medical advance in 100 yearsThe Oxford ClubFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Windtree Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.